Monoclonal Anti-CD16 antibody produced in mouse

clone LNK16, purified immunoglobulin, buffered aqueous solution

Anti-FCGR3A, Anti-FcγRIII

Quality Level

biological source


antibody form

purified immunoglobulin

antibody product type

primary antibodies


LNK16, monoclonal


buffered aqueous solution

species reactivity

nonhuman primates, human


1 mg/mL


flow cytometry: suitable





NCBI accession no.

UniProt accession no.

shipped in

wet ice

storage temp.


Gene Information

human ... FCGR3A(2214)

General description

The antibody LNK16 reacts with CD16, a low affinity receptor for aggregated IgG (FcgammaRIII antigen). CD16 exists in two different isoforms: CD16a (FcgammaRIIIA; 50-65 kDa; expressed on NK-cells, monocytes and macrophages) and CD16b (FcgammaRIIIB; 48 kDa; mainly expressed on neutrophils).


Normal human peripheral blood granulocytes


The reagent is designed for Flow Cytometry analysis. Suggested working dilution for Flow Cytometry is 2 μg/mL of sample. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Solution in Tris buffered saline, pH 8.0, with 15 mM sodium azide.


Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Britnie R James et al.
Cancer immunology, immunotherapy : CII, 63(11), 1213-1227 (2014-08-22)
Tumor progression occurs through the modulation of a number of physiological parameters, including the development of immunosuppressive mechanisms to prevent immune detection and response. Among these immune evasion mechanisms, the mobilization of myeloid-derived suppressor cells (MDSC) is a major contributor...
Eri Shimura et al.
Biochemical and biophysical research communications, 453(1), 1-6 (2014-09-11)
IL-17RA is a shared receptor subunit for several cytokines of the IL-17 family, including IL-17A, IL-17C, IL-17E (also called IL-25) and IL-17F. It has been shown that mice deficient in IL-17RA are more susceptible to sepsis than wild-type mice, suggesting...
Giovanni F Torelli et al.
Haematologica, 99(7), 1248-1254 (2014-03-25)
In this study, we aimed to investigate the pathways of recognition of acute lymphoblastic leukemia blasts by natural killer cells and to verify whether differences in natural killer cell activating receptor ligand expression among groups defined by age of patients...
Megan M Tu et al.
Cancer research, 74(14), 3684-3694 (2014-05-08)
According to the missing-self hypothesis, natural killer (NK) cells survey for target cells that lack MHC-I molecules. The Ly49 receptor family recognizes loss of MHC-I and is critical for educating NK cells, conferring the ability to eliminate transformed or infected...
Allen Y Chung et al.
Cancer research, 74(19), 5377-5385 (2014-09-18)
Immune dysregulation drives the pathogenesis of chronic inflammatory, autoimmune, and dysplastic disorders. While often intended to address localized pathology, most immune modulatory therapies are administered systemically and carry inherent risk of multiorgan toxicities. Here, we demonstrate, in a murine model...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.